3'-chloro-4-sulfamoyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid [4-(2-fluoro-3-trifluoromethyl-phenyl)-thiazol-2-yl]-amide | 918939-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3'-chloro-4-sulfamoyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid [4-(2-fluoro-3-trifluoromethyl-phenyl)-thiazol-2-yl]-amide
• 英文别名: 5-chloro-N-(4-(2-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-yl)-6-(4-sulfamoylpiperidin-1-yl)nicotinamide；5-chloro-N-[4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-6-(4-sulfamoylpiperidin-1-yl)pyridine-3-carboxamide
• CAS: 918939-84-1
• 化学式: C₂₁H₁₈ClF₄N₅O₃S₂
• 分子量: 563.984
• InChiKey: BVPMSDQLPDBRKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  155
• 氢给体数：
  2
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  piperidine-4-sulfonamide 、 5.6-dichloro-N-(4-(2-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-yl)pyridine-3-carboxamide 生成 3'-chloro-4-sulfamoyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid [4-(2-fluoro-3-trifluoromethyl-phenyl)-thiazol-2-yl]-amide
  参考文献：
  名称：

  The identification of orally bioavailable thrombopoietin agonists

  摘要：

  Recently, we disclosed a series of potent pyrimidine benzamide-based thrombopoietin receptor agonists. Unfortunately, the structural features required for the desired activity conferred physicochemical properties that were not favorable for the development of an oral agent. The physical properties of the series were improved by replacing the aminopyrimidinyl group with a piperidine-4-carboxylic acid moiety. The resulting compounds possessed favorable in vivo pharmacokinetic properties, including good bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.032

文献信息

• The identification of orally bioavailable thrombopoietin agonists
  作者：Michael J. Munchhof、Amy S. Antipas、Laura C. Blumberg、William H. Brissette、Matthew F. Brown、Jeffrey M. Casavant、Jonathan L. Doty、James Driscoll、Thomas M. Harris、Lilli A. Wolf-Gouveia、Christopher S. Jones、Qifang Li、Robert G. Linde、Paul D. Lira、Anthony Marfat、Eric McElroy、Mark Mitton-Fry、Sandra P. McCurdy、Lawrence A. Reiter、Sharon L. Ripp、Andrei Shavnya、Lisa M. Thomasco、Kristen A. Trevena

  DOI：10.1016/j.bmcl.2009.01.032

  日期：2009.3

  Recently, we disclosed a series of potent pyrimidine benzamide-based thrombopoietin receptor agonists. Unfortunately, the structural features required for the desired activity conferred physicochemical properties that were not favorable for the development of an oral agent. The physical properties of the series were improved by replacing the aminopyrimidinyl group with a piperidine-4-carboxylic acid moiety. The resulting compounds possessed favorable in vivo pharmacokinetic properties, including good bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.